Triclosan-antibacterial Sutures Impact on the Incidence of Surgical Site Infection in Laparoscopic Surgeries.

Triclosan-antibacterial Sutures Impact on the Incidence of Surgical Site Infection in Laparoscopic Sleeve Gastrectomy, Laparoscopic Appendectomy or Laparoscopic Cholecystectomy; Multi-center, Double-blind, Randomized Study.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04255927

Enrollment

912

Registered

2020-02-05

Start date

2020-02-05

Completion date

2022-04-20

Last updated

2022-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Surgery, Surgical Site Infection, Surgical Wound

Brief summary

Comparing the incidence of PSI in cases using coated Polyglactin 910 suture with Triclosan and cases using Polyglactin 910 suture without Triclosan in laparoscopic sleeve gastrectomy, laparoscopic appendectomy or laparoscopic cholecystectomy.

Detailed description

In this prospective study, we will determine the incidence of PSI in Egypt as well as the impact of using coated polyglactin 910 sutures with Triclosan in lowering the incidence of PSI in laparoscopic sleeve gastrectomy, laparoscopic appendectomy or laparoscopic cholecystectomy.

Interventions

DRUGCoated Vicryl plus

Vicryl plus (Coated Polyglactin 910 with Triclosan)

DRUGCoated vicryl

Vicryl (Coated Polyglactin 910 without Triclosan)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Outcomes Assessor)

Intervention model description

randomized-controlled

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* age 18-75 * candidate for laparoscopic surgical intervention during the period of the study were included.

Exclusion criteria

* Patient has immunodeficiency disorder. * Patient receiving anti-cancer / immunosuppressive therapy. * Patients with established pre-operative infection whether community acquired or hospital acquired either at / remote from the operative site.

Design outcomes

Primary

Measure	Time frame	Description
port site infection (PSI)	30 days	the incidence of port site infection (PSI)

Secondary

Measure	Time frame	Description
hospital stay	30 days	Post-operative hospital stay in days

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026